CMS is forcing Medicare drug plans to cover "substantially all" brands in six key classes through 2007. That's good for some big brands but it could hasten the end of the private market system for Part D. The decision means that drug marketers in the six protected classes--antipsychotics, antidepressants, anticonvulsants, antiretrovirals, antineoplastics, and immunosuppressants-will continue to hold the upper hand in discount negotiations with managed care plans for about eighteen months, until the wrangling for 2008 plan prices begins in mid-2007.
Cole Werble
Round two in the struggle between Medicare private plans and pharma over the pricing of drugs in six key therapeutic...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.
Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.
